Latest purchase details: How patients purchase Asiminib

Asciminib (Asciminib) is the first BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket (STAMP) and is globally approved for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who have previously received ≥2 tyrosine kinase inhibitors (TKIs).

InASCEMBL, patients with CML-CP who had received ≥2 prior TKIs were randomized in a 2:1 ratio (stratified by baseline major cytogenetic response[MCyR]) to receive either asiminib 40 mg twice daily or bosutinib 500 mg once daily. Consistent with the previously published primary analysis, aximinib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib after a median follow-up of 2.3 years.

Acemini's original drug has not yet been launched in China, so it cannot be included in medical insurance. Patients cannot purchase the drug through relevant domestic channels and can only purchase it through overseas channels. The price of the original drug Aceminid sold overseas is very expensive, and the price of 20mg*60 oral tablets is about more than 20,000 US dollars (the price may fluctuate due to the exchange rate). There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.